ImmunityBio, Inc. - Common Stock (NQ:IBRX)

9.750 +0.060 (+0.62%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus

October 01, 2026

Via AB Newswire

Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus

August 10, 2026

Via AB Newswire

Topics Artificial Intelligence

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

August 10, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template ↗

July 03, 2026

Via Chartmill

Bull Finder: IBRX, ANY, GTE, JLHL Plus More Surging Stocks Inside

August 05, 2026

Via AB Newswire

Topics Artificial Intelligence

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 04, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

July 29, 2026

From ImmunityBio, Inc.

Via Business Wire

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

June 08, 2026

From Biotech Insider

Via GlobeNewswire

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

June 01, 2026

From ImmunityBio, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

May 26, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

May 26, 2026

From Rosen Law Firm

Via Business Wire

IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

May 26, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 25, 2026

From Schall Law

Via GlobeNewswire

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

May 22, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

May 22, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

May 22, 2026

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

May 22, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

May 21, 2026

From SkyMedia, LLC

Via GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 21, 2026

From Schall Law

Via GlobeNewswire

Why ImmunityBio Stock is Soaring Higher Today ↗

May 20, 2026

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

Via The Motley Fool

INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

May 20, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

May 20, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

May 19, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

May 19, 2026

From Pomerantz LLP

Via GlobeNewswire

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026

May 19, 2026

From Berger Montague

Via GlobeNewswire

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

May 19, 2026

From ImmunityBio, Inc.

Via Business Wire

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

May 18, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

IMMUNITYBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

May 18, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.